Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have earned a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $16.75.

A number of research firms have weighed in on FOLD. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Wells Fargo & Company decreased their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th.

Hedge Funds Weigh In On Amicus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in Amicus Therapeutics in the 4th quarter valued at about $59,000. Neo Ivy Capital Management grew its holdings in Amicus Therapeutics by 501.6% during the 4th quarter. Neo Ivy Capital Management now owns 395,745 shares of the biopharmaceutical company’s stock worth $3,727,000 after acquiring an additional 329,959 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Amicus Therapeutics by 96.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 958,671 shares of the biopharmaceutical company’s stock valued at $9,031,000 after purchasing an additional 471,902 shares during the period. Vestal Point Capital LP bought a new stake in Amicus Therapeutics in the fourth quarter valued at approximately $31,557,000. Finally, Sovereign s Capital Management LLC acquired a new position in Amicus Therapeutics in the fourth quarter valued at $2,806,000.

Amicus Therapeutics Stock Down 1.9 %

Shares of NASDAQ:FOLD opened at $8.43 on Monday. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The stock has a market cap of $2.59 billion, a price-to-earnings ratio of -46.83, a P/E/G ratio of 1.51 and a beta of 0.69. The company has a 50 day moving average of $9.28 and a 200-day moving average of $9.95. Amicus Therapeutics has a one year low of $8.36 and a one year high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.